PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31897949-6 2020 Also, the patients receiving vitamin D3 yielded a marginally significant lower IL-6 serum concentration (76.43 ng/L) compared to placebo (93.10 ng/L) (P value:0.055). Cholecalciferol 29-39 interleukin 6 Homo sapiens 79-83 32344650-0 2020 The Effect of Vitamin D3 Supplementation on Hepcidin, Iron, and IL-6 Responses after a 100 km Ultra-Marathon. Cholecalciferol 14-24 interleukin 6 Homo sapiens 64-68 32203968-0 2020 Vitamin D3 Supplementation in Diarrhea-Predominant Irritable Bowel Syndrome Patients: The Effects on Symptoms Improvement, Serum Corticotropin-Releasing Hormone, and Interleukin-6 - A Randomized Clinical Trial. Cholecalciferol 0-10 interleukin 6 Homo sapiens 166-179 32251441-1 2020 BACKGROUND & AIMS: In our previous study, a Seesaw model was proposed for the fluctuation of crucial anti- (IL-10) and pro-inflammatory (Il-6 & IL-17A) cytokines through vitamin D3. Cholecalciferol 170-180 interleukin 6 Homo sapiens 137-141 32251441-7 2020 In addition, the plasma levels of IL-27, TGF-beta1, IL-10, IL-17A, and IL-6 significantly changed following the administration of vitamin D3. Cholecalciferol 130-140 interleukin 6 Homo sapiens 71-75 32203968-12 2020 CONCLUSION: Our findings indicate that vitamin D3 supplementation can modulate the serum level of CRH and IL-6 and can improve symptoms in IBS-D patients. Cholecalciferol 39-49 interleukin 6 Homo sapiens 106-110 31106659-5 2020 In addition, serum level of IL-6 was decreased significantly in omega-3, vitamin D3, and cosupplementation groups compared with baseline. Cholecalciferol 73-83 interleukin 6 Homo sapiens 28-32 29431349-3 2018 The aim of our study was to evaluate the effect of active vitamin D3 (VD) on the expression of pro-inflammatory and anti-inflammatory cytokines (IL-6, IL-8, IL-10 and IL-12) in human gingival fibroblasts (hGF) and human periodontal ligament cells (hPDLc) triggered by Porphyromonas gingivalis and Streptococcus pyogenes. Cholecalciferol 58-68 interleukin 6 Homo sapiens 145-149 31250540-10 2019 Supplementation with 2,000-IU/d vitamin D3 is more effective than 1,000 IU/d in pregnant women in terms of increasing circulating 25(OH)D, ameliorating pro-inflammatory markers notably TNF-alpha in mother and IL-6 in cord blood, and improving neonatal outcomes including the birth sizes. Cholecalciferol 32-42 interleukin 6 Homo sapiens 209-213 31450894-0 2019 IL-6 Impairs the Activity of Vitamin D3 in the Regulation of Epithelial-Mesenchymal Transition in Triple Negative Breast Cancer. Cholecalciferol 29-39 interleukin 6 Homo sapiens 0-4 31450894-12 2019 Conclusion: The presence of IL-6 in the breast tumor microenvironment may impair theactivity of vitamin D3 signaling, limiting its anti-tumor effects in TNBC. Cholecalciferol 96-106 interleukin 6 Homo sapiens 28-32 30729713-1 2019 AIM: Vitamin D3 or 25(OH)D3 may have a potential role in rheumatoid arthritis (RA) pathogenesis by inhibiting the expression of pro-inflammatory cytokines including interleukin-6 (IL-6). Cholecalciferol 5-15 interleukin 6 Homo sapiens 165-178 30729713-1 2019 AIM: Vitamin D3 or 25(OH)D3 may have a potential role in rheumatoid arthritis (RA) pathogenesis by inhibiting the expression of pro-inflammatory cytokines including interleukin-6 (IL-6). Cholecalciferol 5-15 interleukin 6 Homo sapiens 180-184 30533524-5 2018 Results: Vitamin D3 affected the levels of IL-17A, IL-10, and IL-6 among the 3 groups (p < 0.001 for all). Cholecalciferol 9-19 interleukin 6 Homo sapiens 62-66 30533524-8 2018 Conclusions: Although supplementation with vitamin D3 reduced the mRNA expression levels of IL-17A and IL-6, it increased the mRNA expression level of IL-10 in all groups. Cholecalciferol 43-53 interleukin 6 Homo sapiens 103-107 30533524-10 2018 Of interest, in a deficiency state of serum vitamin D3, IL-17A expression had a positive feedback effect on the expression of IL-6. Cholecalciferol 44-54 interleukin 6 Homo sapiens 126-130 25495336-10 2015 CONCLUSIONS: Vitamin D3 promotes osteogenic differentiation but also downregulates inflammation promoter-induced IL-6 cytokine and CXCL1 chemokine expression in human PDL cells, suggesting that vitamin D3 both stimulates bone regeneration and antagonizes inflammation in human periodontal tissue. Cholecalciferol 13-23 interleukin 6 Homo sapiens 113-117 27161894-11 2016 Serum concentration of IL-6 and CRP decreased from 8.1 +- 6.6 pg/mL to 4.6 +- 4.1 pg/mL (p < 0.05) and from 0.50 (0.10-1.27) mg/dL to 0.28 (0.09-0.62) mg/dL (p < 0.05), respectively only in the cholecalciferol group. Cholecalciferol 200-215 interleukin 6 Homo sapiens 23-27 25495336-7 2015 The LPS-induced increase in IL-6 and CXCL1 transcripts was attenuated by vitamin D3 (30 ng/mL). Cholecalciferol 73-83 interleukin 6 Homo sapiens 28-32 25495336-8 2015 Treatment with vitamin D3 (3-300 ng/mL) for 24 h reduced the LPS-evoked increase in PDL cell IL-6 protein by about 50%. Cholecalciferol 15-25 interleukin 6 Homo sapiens 93-97 26943970-8 2016 Most importantly, the activated microglia exposed to vitamin D3 had reduced expression of pro-inflammatory cytokines, IL-6, IL-12, and TNFalpha, and increased expression of IL-10. Cholecalciferol 53-63 interleukin 6 Homo sapiens 118-122 25495336-10 2015 CONCLUSIONS: Vitamin D3 promotes osteogenic differentiation but also downregulates inflammation promoter-induced IL-6 cytokine and CXCL1 chemokine expression in human PDL cells, suggesting that vitamin D3 both stimulates bone regeneration and antagonizes inflammation in human periodontal tissue. Cholecalciferol 194-204 interleukin 6 Homo sapiens 113-117 23612780-5 2014 However, 100 nM of vitamin D3 significantly increased the release of IL-10, but suppressed the production of IL-2, IL-6, interferon gamma and TNF alpha in the culture supernatants of both groups. Cholecalciferol 19-29 interleukin 6 Homo sapiens 115-119 25908506-7 2015 In stratified analyses, participants randomized to vitamin D3 who lost 5% to 10% of baseline weight, versus participants who gained weight/had no weight-loss, had significantly greater decreases in levels of IL6 compared with those randomized to placebo: absolute change -0.75 pg/mL (-17.2%), placebo versus -1.77 pg/mL (-37.3%), vitamin D, P = 0.004. Cholecalciferol 51-61 interleukin 6 Homo sapiens 208-211 25908506-11 2015 In conclusion, vitamin D3 supplementation in combination with weight-loss of at least 5% of baseline weight was associated with significant reductions in levels of IL6. Cholecalciferol 15-25 interleukin 6 Homo sapiens 164-167 24374976-9 2014 RESULTS: Compared with baseline values, LPS-matured mo-DC exhibited reduced expression of CD80 and reduced production of the cytokines IL-10, IL-1beta, and IL-6 following 26 weeks of oral vitamin D3 supplementation. Cholecalciferol 188-198 interleukin 6 Homo sapiens 156-160 24576880-5 2014 RESULTS: The HSF, HCEC-12, ODM-2, and ARPE-19 express mRNA and protein for all vitamin D3 synthesizing and metabolizing components. Cholecalciferol 79-89 interleukin 6 Homo sapiens 13-16 22925537-0 2012 Effects of a 1-year supplementation with cholecalciferol on interleukin-6, tumor necrosis factor-alpha and insulin resistance in overweight and obese subjects. Cholecalciferol 41-56 interleukin 6 Homo sapiens 60-73 23710204-6 2013 Vitamin D3 acted in synergy with the TLR agonists LPS and peptidoglycan (PGN) in inducing IL-6, IL-8, and IL-10, whereas vitamin D3 completely inhibited LPS-induced secretion of IL-12. Cholecalciferol 0-10 interleukin 6 Homo sapiens 90-94 21050239-0 2010 Vitamin D3 treatment of Crohn"s disease patients increases stimulated T cell IL-6 production and proliferation. Cholecalciferol 0-10 interleukin 6 Homo sapiens 77-81 22387385-6 2012 Moreover, vitamin D3 significantly reduced the levels of proinflammatory cytokines (TNF-alpha, IL-6, IL-12p70 and IL-1beta) produced by infected U937 cells. Cholecalciferol 10-20 interleukin 6 Homo sapiens 95-99 21050239-6 2010 Vitamin D3 treatment increased interleukin-6 production (delta = 188 pg/mL, range: -444 to 4071) compared with a decrease in the placebo group (delta = -896 pg/mL, range: -3841 to 1323) (P < 0.02, Wilcoxon rank sum test). Cholecalciferol 0-10 interleukin 6 Homo sapiens 31-44 21050239-8 2010 CONCLUSIONS: Vitamin D3 treatment of Crohn"s disease patients increased the IL-6 levels. Cholecalciferol 13-23 interleukin 6 Homo sapiens 76-80 20435648-0 2010 Vitamin D3 down-regulates intracellular Toll-like receptor 9 expression and Toll-like receptor 9-induced IL-6 production in human monocytes. Cholecalciferol 0-10 interleukin 6 Homo sapiens 105-109 20007751-5 2010 Cholecalciferol therapy reduced circulating levels of inflammatory cytokines, including IL-8, IL-6, and TNF. Cholecalciferol 0-15 interleukin 6 Homo sapiens 94-98 8977259-0 1996 Myeloma cell growth arrest, apoptosis, and interleukin-6 receptor modulation induced by EB1089, a vitamin D3 derivative, alone or in association with dexamethasone. Cholecalciferol 98-108 interleukin 6 Homo sapiens 43-56 34109109-8 2021 Moreover, increased vitamin D3 levels by calcitriol supplementation or induction by UVB-radiation was associated with inhibited IL-6 signaling and increased the response to irradiation observed in animal models. Cholecalciferol 20-30 interleukin 6 Homo sapiens 128-132 2572101-1 1989 Skin biopsies from 5 patients with chronic plaque psoriasis were examined to test the effect of topical treatment with a new synthetic vitamin D3 analogue, MC 903, on epidermal interleukin 6 (IL-6) and tumour necrosis factor alpha (TNF alpha). Cholecalciferol 135-145 interleukin 6 Homo sapiens 177-190 34669255-12 2021 Pharmacological profile revealed that the treatment of DO and D3 inhibited the production of pro-inflammatory cytokines (TNF-alpha, IL-6) induced by lipopolysaccharide (LPS) in primary macrophages without any cytotoxic effect after administration of their effective concentrations. Cholecalciferol 62-64 interleukin 6 Homo sapiens 132-136